<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are highly proliferative bone marrow (BM) disorders where the <z:e sem="disease" ids="C1402294" disease_type="Disease or Syndrome" abbrv="">primary lesion</z:e> presumably affects a CD34+ early progenitor or stem cell </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the proliferative characteristics of CD34+ cells of 33 untreated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients (19 RA, 5 RARS, 7 RAEB, 2 RAEBt) and five patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (sAML) </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received a 1-h infusion of the <z:chebi fb="0" ids="17748">thymidine</z:chebi> analogue iodoor bromodeoxyuridine intravenously before a BM aspirate and biopsy was taken </plain></SENT>
<SENT sid="3" pm="."><plain>A double-labeling immunohistochemistry technique by monoclonal anti-CD34 (QBend/10) and anti-IUdR/BrdU antibodies was developed and performed </plain></SENT>
<SENT sid="4" pm="."><plain>By this technique we recognised CD34+ and CD34- cells actively engaged in DNA synthesis or not </plain></SENT>
<SENT sid="5" pm="."><plain>As <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> evolves a significant increase occurred in the percentage of CD34+ cells of <z:hpo ids='HP_0000001'>all</z:hpo> myeloid cells (mean value: RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> 1.67%; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>(t) 8.68%; sAML 23.83%) as well as in the percentage of proliferating CD34+ cells of <z:hpo ids='HP_0000001'>all</z:hpo> myeloid cells (RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> 0.19%; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>(t) 0.43%; and sAML 3.30%) </plain></SENT>
<SENT sid="6" pm="."><plain>This was associated with a decreasing trend in the overall myeloid labeling index (LI: RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> 25.8%, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>(t) 24.6% and sAML 21.5%) </plain></SENT>
<SENT sid="7" pm="."><plain>This decrease in overall myeloid LI is due to an exponential increase in the proportion of CD34+ cells of the proliferating compartment during <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> evolution (RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> 0.35%, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>(t) 1.44% and sAML 11.98% of <z:hpo ids='HP_0000001'>all</z:hpo> S-phase cells) </plain></SENT>
<SENT sid="8" pm="."><plain>These CD34+ cells appeared to proliferate more slowly than their more mature CD34 negative counterparts, since we found a progressive increment in the mean total cell cycling time (Tc) of <z:hpo ids='HP_0000001'>all</z:hpo> myeloid cells during <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> progression (RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> 39.8, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>(t) 45.2 and sAML 65.8 h) </plain></SENT>
<SENT sid="9" pm="."><plain>This study showed that during <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> evolution to sAML the CD34+ compartment develops a growth advantage leading to apparent expansion </plain></SENT>
</text></document>